CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

personal-finance

CSL: Why I’m still holding

In this episode of Investing Compass, Mark and Shani talk through whether CSL still deserves a place in Mark’s portfolio.
investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
markets

Market Minute: Reporting Season, Part 2

Equity Market Strategist Lochlan Halloway is back with Part 2 of the Reporting Season update, with more upgrades than average and big share price swings for blue-chip stocks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,674.7824.14-0.31%
DAX 4023,596.98173.35-0.73%
Dow JONES (US)45,400.86220.43-0.48%
FTSE 1009,208.218.66-0.09%
HKSE25,417.98359.471.43%
NASDAQ21,700.397.30-0.03%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,223.5390.330.69%
S&P 5006,481.5020.58-0.32%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers